Recent research suggest that Donanemab, an investigational monoclonal antibody , has the potential to slow the advance of preclinical Alzheimer's . This therapy focuses on removing beta-amyloid https://bookmarks-hit.com/story25442408/nadecenemab-an-promising-new-dementia-therapy